Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
About Context Therapeutics Inc.
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for solid tumors. Headquartered in Philadelphia, the company focuses on developing T cell engaging (TCE) bispecific antibodies, a cutting-edge immunotherapy approach that redirects the body's immune system to target and destroy cancer cells. With a robust pipeline of clinical-stage assets, Context is at the forefront of addressing unmet medical needs in oncology, particularly in hormone-dependent and underserved cancers.
Core Focus: T Cell Engaging Bispecific Antibodies
Context Therapeutics specializes in TCE bispecific antibodies, which are engineered to bind simultaneously to tumor-specific antigens and T cells, facilitating targeted immune responses against cancer cells. Their lead program, CTIM-76, targets Claudin 6 (CLDN6), a protein highly expressed in multiple solid tumors but absent in most healthy tissues, ensuring specificity and minimizing off-target effects. Additionally, their pipeline includes CT-95, a Mesothelin (MSLN) x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody, both of which are being developed to treat advanced cancers with limited therapeutic options.
Innovative Pipeline and Development Strategy
Context's pipeline reflects a strategic emphasis on addressing solid tumors with high unmet needs. The company's therapies are designed for scalability and low immunogenicity, ensuring broader accessibility and reduced adverse effects. CTIM-76 is currently in Phase 1 clinical trials, targeting gynecologic and testicular cancers, while CT-95 and CT-202 are advancing toward clinical development. Context's acquisition of promising assets like CT-95 and CT-202 underscores their commitment to building a diverse and innovative portfolio of TCE therapeutics.
Market Position and Competitive Landscape
Operating in the highly competitive oncology sector, Context Therapeutics differentiates itself through its focus on bispecific antibody technology and its ability to address limitations of first-generation therapies. By targeting tumor-specific proteins like CLDN6, MSLN, and Nectin-4, the company positions itself as a leader in developing next-generation immunotherapies. Their approach to scalable manufacturing and robust preclinical data further strengthens their competitive edge. Key competitors include other biotech firms specializing in immuno-oncology, but Context's emphasis on underserved cancer types and differentiated product profiles sets them apart.
Commitment to Addressing Unmet Medical Needs
Context Therapeutics is driven by a mission to transform the treatment landscape for solid tumors. By leveraging advanced TCE technology and focusing on cancers with limited therapeutic options, the company aims to provide hope to patients and families affected by these challenging diseases. Their strategic acquisitions, robust pipeline, and focus on innovation highlight their dedication to improving patient outcomes and advancing the field of oncology.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has granted stock options to two new employees as employment inducements. The grants total 46,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan, complying with Nasdaq Rule 5635(c)(4).
The options were granted on February 18 and 24, 2025, with exercise prices of $0.83 and $0.8314 per share respectively, matching Context's closing stock prices on those dates. These 10-year options follow a four-year vesting schedule: 25% vests after one year, with the remaining 75% vesting in 36 monthly installments. Vesting is contingent on continued employment with Context.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced its participation in three major upcoming investor conferences in February and March 2025:
• B. Riley Securities Precision Oncology & Radiopharma Conference: Two panel discussions scheduled for February 28, 2025, at 8:00 a.m. and 10:00 a.m. ET in New York
• TD Cowen 45th Annual Healthcare Conference: Presentation scheduled for March 3, 2025, at 11:10 a.m. ET in Boston
• Leerink Partners Global Healthcare Conference: Fireside chat scheduled for March 10, 2025, at 10:00 a.m. ET in Miami
The company will also conduct one-on-one meetings with investors at each conference.
Context Therapeutics (CNTX) has initiated its Phase 1 clinical trial for CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody, with the first patient now dosed. The trial focuses on patients with CLDN6-positive gynecologic and testicular cancers.
The open-label study will evaluate safety and efficacy in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. The trial aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity through metrics including overall response rate, duration of response, and disease control rate. Expected to enroll up to 70 patients, the company anticipates sharing initial data in the first half of 2026.
Context Therapeutics (Nasdaq: CNTX) has appointed Andy Pasternak as Chairman of its Board of Directors, effective January 13, 2025, succeeding Richard Berman. Pasternak brings over 25 years of biopharmaceutical experience and currently serves as an Advisory Partner at Bain & Company.
Most recently, Pasternak was Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, where he played a key role in the company's $28 billion acquisition by Amgen in 2023. His responsibilities included corporate strategy, M&A, business development, commercial development, and portfolio management.
Prior to Horizon, he served as Head of Healthcare Practice in the Americas at Bain & Company. He currently serves on the Board of Directors of Endo and is an adjunct lecturer at Northwestern University's Kellogg School of Management.
Context Therapeutics (CNTX) reported Q3 2024 financial results and business updates. The company expanded its pipeline through acquisitions of CT-95 and CT-202, two T cell engaging bispecific antibodies. Cash position stood at $84.8 million as of September 30, 2024. Q3 net loss increased to $17.5 million from $5.9 million year-over-year, primarily due to R&D expenses of $16.8 million. The company expects current cash to fund operations into 2027, including Phase 1 trials for CTIM-76 and CT-95, and IND filing for CT-202.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced its participation in three major investor conferences this November. The company will present at the Guggenheim Global Healthcare Conference (November 11), UBS Global Healthcare Conference (November 13), and Stifel 2024 Healthcare Conference (November 19).
The presentations will include fireside chats and one-on-one meetings with investors. All sessions will be webcast live and available for replay for 90 days on the company's investor relations website.
Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation will feature their clinical asset CTIM-76, a Claudin 6 x CD3 bispecific antibody.
The poster, titled 'Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6,' will be presented on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB of the George R. Brown Convention Center in Houston, TX. The authors of the presentation are Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and near-term milestones
3. Potential for up to $118.5 million in additional clinical, regulatory, and commercial milestones
4. BioAtla eligible for tiered royalties on net sales
5. Context anticipates IND filing for BA3362 in mid-2026
This agreement allows BioAtla to focus on its lead clinical CAB programs while advancing BA3362 under Context's leadership. Context views Nectin-4 as a priority target for solid tumors and sees BA3362 as a potentially best-in-class asset.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has appointed Dr. Karen Smith and Dr. Luke Walker to its Board of Directors. Dr. Smith brings over 20 years of experience in drug development and commercialization, having contributed to successful products like Herceptin and Vyxeos. Dr. Walker offers extensive clinical development expertise, particularly in T cell engaging bispecific antibodies.
These appointments aim to support Context's growth and pipeline advancement. Dr. Smith's oncology drug development and regulatory experience, along with Dr. Walker's track record in oncology drug development, are expected to be valuable assets for the company's strategic goals.
Context Therapeutics (Nasdaq: CNTX) reported its Q2 2024 financial results and recent business highlights. Key points include:
- Acquisition of CT-95, a mesothelin x CD3 bispecific antibody
- Appointment of Dr. Claudio Dansky Ullmann as Chief Medical Officer
- Cash and cash equivalents of $101.5 million as of June 30, 2024
- FDA clearance for CTIM-76 IND, with first patient dosing expected in Q3 2024
- Closed a $100 million private placement in May 2024
- Net loss of $2.3 million for Q2 2024, compared to $5.0 million in Q2 2023
- Cash runway expected to fund operations into 2028
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
What does Context Therapeutics Inc. specialize in?
What is the significance of CTIM-76 in Context's pipeline?
What differentiates Context Therapeutics from competitors?
What types of cancers does Context Therapeutics target?
How does Context Therapeutics generate revenue?
What is the role of bispecific antibodies in cancer treatment?
What recent acquisitions has Context Therapeutics made?
Where is Context Therapeutics headquartered?
What are the potential advantages of CTIM-76 over other therapies?
What is the future outlook for Context Therapeutics?
